Skip to main content
. 2014 May 30;16(3):R56. doi: 10.1186/bcr3667

Figure 1.

Figure 1

Immunohistochemistry (IHC) analysis of JMJD2A expression in non-neoplastic and breast cancer tissues. (A) Hematoxylin-eosin (HE) staining of non-neoplastic tissues. (B, C) Representative results of the negative staining (B) and weakly positive staining (C) of JMJD2A protein in non-neoplastic tissues. (D) Distributions of JMJD2A staining grades (−, +, ++ and +++) in both non-neoplastic tissues (D, a) and breast cancer tissues (D, b). In non-neoplastic tissues, 29 out of 30 tissues exhibited to be JMJD2A negative and only 1 in 30 tissues exhibited to be JMJD2A weakly positive. In breast cancer tissues, the positive rate of JMJD2A staining in breast cancer tissues (93%) was significantly higher than that in non-neoplastic tissues (3%) (P <0.001). (E) Validation of breast cancer tissues by HE stain. (F, G, H, I) Representative results of negative staining (−, F), weakly positive staining (+, G), moderate staining (++, H) and strong staining (+++. I) of JMJD2A protein in breast cancer tissues are shown respectively. Scale bar = 20 μm.